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The history of pharmaceutical costing for use in cost-
effectiveness studies has been marked more by convenience—
what pricing data are readily available?—than by science—what
opportunities are forgone when we use a particular drug? For too
long, our ﬁeld has relied on average wholesale price, when there
is substantial evidence that it is an inappropriate measure [1,2].
Thus, the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) Task Force on Good Research
Practices—Use of Drug Costs for Cost Effectiveness Analysis
reports on drug costing [3–8] is commendable.
These reports describe in gory detail the intricacies of drug
costing from ﬁve different perspectives: societal, managed care,
US government, industry, and international. The documented
complexity is magniﬁed by the fact, well recognized by the
authors, that much of the necessary information is proprietary
and likely to be unavailable to researchers. The Task Force might
have been better served giving as much thought to the objectives
of published pharmacoeconomic studies as it did to the data
needed for appropriate estimates for single payers/providers.
Do we expect that our published studies can individually
inform each of the 50 different state Medicaid programs about
whether an intervention is cost-effective in their state? How
about individually informing each of the much larger numbers of
managed care organizations? How overwhelmingly demanding
would the information requirements be, particularly given that
the necessary data would not be limited to identifying
organization-speciﬁc drug costs, but would require organization-
speciﬁc measures of both practice pattern and the other cost data
used in the study? Although there is no consensus in our ﬁeld
about which is more important, organization-speciﬁc measures
of practice pattern may have a greater impact on our recommen-
dations to individual payers than do organization-speciﬁc price
weights/unit costs.
The problem arises from the nebulous nature of some of the
perspectives we hope to address: which payer? which provider?
It is akin to the problem faced when transferring/generalizing
economic data across jurisdictions [9]. If we make the results
speciﬁc for an individual payer, we may lose transferability/
generalizability to other payers; if we instead develop an average
result across the pool of payers, all may be left wondering
whether they are enough like the average that they should be
conﬁdent that the study’s recommendation applies to them.
If we actually want to publish a value recommendation
directed speciﬁcally to the Pennsylvania Medicaid program or if
we want to direct such a recommendation speciﬁcally to Inde-
pendence Blue Cross in Philadelphia, the answer to the Task
Force question is fairly obvious: use these organizations’ price
weights (and practice patterns). But it is rare that our published
studies have such a narrow focus. These reports would have been
more helpful had they spent more time helping us understand 1)
whether and how we can more productively use average values
for our price weights, and 2) the additional analyses we can
perform to help payers understand how much variance can exist
around these price weight estimates without their needing to
worry about whether the value recommendation applies to them.
Having said that, these reports provide a good start at making
us bring more rigors to a ﬁeld that has relied preponderantly on
the ﬁctitious average wholesale price.
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